GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (FRA:CBO) » Definitions » Cyclically Adjusted PS Ratio

Imunon (FRA:CBO) Cyclically Adjusted PS Ratio : (As of Jun. 02, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Imunon Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imunon Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Imunon's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Cyclically Adjusted PS Ratio Chart

Imunon Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 2.43 0.42 - -

Imunon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Imunon's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Imunon's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Imunon's Cyclically Adjusted PS Ratio falls into.


;
;

Imunon Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Imunon's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Imunon's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0/134.9266*134.9266
=0.000

Current CPI (Mar. 2025) = 134.9266.

Imunon Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 1.110 100.684 1.488
201509 1.009 100.392 1.356
201512 1.036 99.792 1.401
201603 1.009 100.470 1.355
201606 0.965 101.688 1.280
201609 0.835 101.861 1.106
201612 0.874 101.863 1.158
201703 1.054 102.862 1.383
201706 0.251 103.349 0.328
201709 0.196 104.136 0.254
201712 0.092 104.011 0.119
201803 0.086 105.290 0.110
201806 0.090 106.317 0.114
201809 0.090 106.507 0.114
201812 0.092 105.998 0.117
201903 0.087 107.251 0.109
201906 0.081 108.070 0.101
201909 0.079 108.329 0.098
201912 0.066 108.420 0.082
202003 0.066 108.902 0.082
202006 0.056 108.767 0.069
202009 0.047 109.815 0.058
202012 0.041 109.897 0.050
202103 0.061 111.754 0.074
202106 0.018 114.631 0.021
202109 0.018 115.734 0.021
202112 0.019 117.630 0.022
202203 0.020 121.301 0.022
202206 0.017 125.017 0.018
202209 0.018 125.227 0.019
202212 0.014 125.222 0.015
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000
202406 0.000 132.554 0.000
202409 0.000 133.029 0.000
202412 0.000 133.157 0.000
202503 0.000 134.927 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Imunon  (FRA:CBO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Imunon Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Imunon's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon Business Description

Industry
Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon Headlines

No Headlines